Xenon Pharmaceuticals Inc. buy melinda
Start price
19.11.18
/
50%
€7.62
Target price
17.12.18
€9.56
Performance (%)
-23.55%
End price
17.12.18
€5.83
Summary
This prediction ended on 17.12.18 with a price of €5.83. The prediction for Xenon Pharmaceuticals Inc. disappointed with a performance of -23.55%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. | -2.247% | -2.247% | -7.447% | - |
| iShares Core DAX® | 0.805% | 2.118% | 15.587% | 16.559% |
| iShares Nasdaq 100 | 1.995% | 4.071% | 28.811% | 56.196% |
| iShares Nikkei 225® | 1.264% | -2.374% | 3.374% | 4.271% |
| iShares S&P 500 | 1.637% | 2.287% | 24.187% | 46.895% |
Comments by melinda for this prediction
In the thread Xenon Pharmaceuticals Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 30/11 Présentation
Provides drug discovery and development services
Xenon Pharmaceuticals, Inc. is a biopharmaceutical company.
It engages in discovering and developing a pipeline of differentiated therapeutics.
It has built a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.
The company has an integrated platform that includes in-house capabilities for human genetics, small molecule drug discovery and preclinical and clinical development.
Xenon Pharmaceuticals was founded by Simon Neil Pimstone, John J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals, Inc. is a biopharmaceutical company.
It engages in discovering and developing a pipeline of differentiated therapeutics.
It has built a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.
The company has an integrated platform that includes in-house capabilities for human genetics, small molecule drug discovery and preclinical and clinical development.
Xenon Pharmaceuticals was founded by Simon Neil Pimstone, John J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Nombre d'employés : 81 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.66
25.09.17
25.09.17
€5.68
05.02.18
05.02.18
8.47%
05.02.18
05.02.18
Xenon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.95
25.09.17
25.09.17
€6.30
05.02.18
05.02.18
8.47%
05.02.18
05.02.18
Xenon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€4.24
25.03.17
25.03.17
€8.12
25.09.17
25.09.17
-37.23%
25.09.17
25.09.17